| Attributes | Values |
|---|
| rdf:type
| |
| rdfs:label
| |
| equivalentClass
| |
| Has_Target
| |
| Concept_In_Subset
| |
| Semantic_Type
| - Organic Chemical
- Pharmacologic Substance
|
| Preferred_Name
| |
| NSC_Code
| |
| UMLS_CUI
| |
| CAS_Registry
| |
| Accepted_Therapeutic_Use_For
| - Multiple Myeloma; Advanced Thyroid Cancer
|
| In_Clinical_Trial_For
| - Bile duct or gallbladder adenocarcinoma; gastric cancer; gastrointestinal junction carcinoma; glioma; head and neck cancer; hepatocellular carcinoma; lung cancer; small cell and non-small cell; lymphoproliferative disorders; thyroid cancer
- Colorectal cancer; breast cancer; cervical cancer; vaginal cancer; non-Hodgkin's lymphoma; Hodgkin's lymphoma; melanoma
- Multiple myeloma; myelogenous leukemia; ovarian epithelial; fallopian tube; or primary peritoneal cancer; prostate cancer; transitional cell cancer of the bladder; renal cancer; or ureter; unspecified solid tumors; Waldenstrom's Macroglobulinemia
|
| FDA_UNII_Code
| |
| Contributing_Source
| |
| ALT_DEFINITION
| - A drug used to treat multiple myeloma. It is also used to treat mantle cell lymphoma in patients who have already received at least one other type of treatment and is being studied in the treatment of other types of cancer. Bortezomib blocks several molecular pathways in a cell and may cause cancer cells to die. It is a type of proteasome inhibitor and a type of dipeptidyl boronic acid.NCI-GLOSS
|
| PDQ_Open_Trial_Search_ID
| |
| PDQ_Closed_Trial_Search_ID
| |
| Chemical_Formula
| |
| Legacy_Concept_Name
| |
| CHEBI_ID
| |
| FULL_SYN
| - bortezomibPTNCI-GLOSSCDR0000269133
- PS-341SYNCI-GLOSSCDR0000046719
- [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic AcidSNNCI
- PS341CNNCI
- PS-341CNNCI
- MLN341CNNCI
- velcadePTNCI-GLOSSCDR0000413734
- LDP 341CNNCI
- VelcadeBRNCI
- BORTEZOMIBPTFDA69G8BD63PP
- [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic AcidPTDCP31947
- BortezomibPTNCI
|
| DEFINITION
| - A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.NCI
|
| code
| |
| is someValuesFrom
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)